annual meeting program - American Society of Clinical Oncology

SATURDAY
Saturday, June 5, 2010
8:00 AM - 12:00 PM
GENERAL POSTER SESSION
Lymphoma and Plasma Cell Disorders
Location: S Hall A2
Tracks(s): Lymphoma and Plasma Cell Disorders
Brd. 22A Romidepsin activity in all three disease compartments (skin, blood, lymph
nodes) in patients with cutaneous T-cell lymphoma (CTCL). (Abstract #8047)
E. Kim, A. Rook, Y. Kim, M. Demierre, A. Lerner, M. Duvic, T. Robak, J. Becker,
W. McCulloch, S. Whittaker
Brd. 22B Clinical features and treatment outcomes of angioimmunoblastic T-cell
lymphoma. (Abstract #8048)
B. Pro, G. F. Perini, L. Feng, J. E. Romaguera, M. A. Rodriguez, P. McLaughlin,
F. B. Hagemeister, L. Fayad, T. M. Kadia
Brd. 22C Rituximab in combination with CHOP regimen in angioimmunoblastic T-cell
lymphoma: Results of the phase II RAIL trial—A prospective study of the
Groupe d’Etude des Lymphomes de l’Adulte (GELA). (Abstract #8049)
B. Joly, A. Plonquet, M. Grare, M. Delfau-Larue, R. Delarue, A. Delmer,
O. Casasnovas, C. Gisselbrecht, P. Gaulard, C. Haioun
Brd. 22D Transcriptome adaptation caused by vorinostat/bexarotene combination
therapy in advanced cutaneous T-cell lymphoma. (Abstract #8050)
M. B. Karpova, D. Gunz, M. J. Okoniewski, A. Cozzio, K. Schad, K. Baumann
Conzett, R. Dummer
Brd. 22E Prognosis and treatment of patients with peripheral T-cell lymphoma: The
M. D. Anderson Cancer Center experience. (Abstract #8051)
J. V. Pozadzides, G. Perini, M. Hess, J. E. Romaguera, F. B. Hagemeister,
P. McLaughlin, L. Fayad, I. F. Khouri, C. Hosing, B. Pro
Brd. 22F Assessment of combination treatment with gemcitabine, cisplatin, and
methylprednisolone (Gem-P) in the management of non-Hodgkin T-cell
lymphoma. (Abstract #8052)
K. Yim, I. Chau, A. Horwich, C. Dearden, G. Morgan, A. Wotherspoon, A. Attygalle,
B. Sharma, D. Cunningham
Brd. 22G Interim results of phase II trial of pegylated liposomal doxorubicin (PLD)
followed by bexarotene in advanced cutaneous T-cell lymphoma (CTCL).
(Abstract #8053)
D. J. Straus, M. Duvic, S. M. Horwitz, K. B. Hymes, A. Goy, F. J. Hernandez-
Ilizaliturri, T. Feldman, B. Wegner, P. Myskowski
Brd. 22H Pralatrexate in patients with relapsed/refractory peripheral T-cell lymphoma
(PTCL): Relationship between response and survival. (Abstract #8054)
A. R. Shustov, B. Pro, S. M. Horwitz, E. D. Jacobsen, A. Boyd, S. M. Fruchtman,
O. O’Connor
Brd. 23A Duration of response in three phase III studies of denileukin diftitox in
cutaneous T-cell lymphoma (CTCL). (Abstract #8055)
M. Duvic, H. M. Prince
Brd. 23B T-cell monomorphic post-transplant lymphoproliferative disorders (T-cell
m-PTLD): Clinical characteristics and prognostic assessment of a serious
complication after transplant. (Abstract #8056)
F. Montanari, G. Bhagat, J. M. Zain, V. E. Seshan, C. S. Magid Diefenbach,
S. Clark-Garvey, E. McCormick, M. Crook, M. Conroy, O. O’Connor
Brd. 23C ABVD chemotherapy with interferon for advanced-stage classical Hodgkin’s
lymphoma: A 10-year follow-up study. (Abstract #8057)
N. Batty, F. B. Hagemeister, J. E. Romaguera, M. A. Rodriguez, P. McLaughlin,
F. Samaniego, A. Copeland, B. S. Dabaja, A. Younes
98